MATN3 Antibody
| Code | Size | Price |
|---|
| PSI-5141-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5141-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
MATN3 Antibody: HOA, OS2, EDM5, DIPOA, OADIP, Matrilin-3
Application Note:
MATN3 antibody can be used for detection of MATN3 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunocytochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunocytochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
MATN3 Antibody: Matrilins (MATNs) are a family of non-collagenous extra-cellular matrix (ECM) proteins consisting of four known members that have been proposed to play key roles in modulating cellular phenotypes during chondrogenesis of mesenchymal stem cells (MSCs). MATN1 and MATN3 are expressed specifically in cartilage and are among the most up-regulated ECM proteins during chondrogenesis. MATN3 is composed of a single N-terminal von Willebrand Factor A (vWFA) domain followed by four epidermal growth factor (EGF) repeats and a coiled-coil domain whereas MATN1 is composed of two vWFA domains separated by one EGF-like domain. MATN1 or MATN3 may play a role in modulating chondrogenesis during the chondrocyte differentiation process. Mutations of this gene have been associated with variety of inherited chondrodysplasias. Recent studies show that aberrant expression and processing of MATN3 are hallmarks of conventional cartilaginous neoplasms.
Background References:
- Pei M, Luo J, and Chen Q. Enhancing and maintaining matrilins. Osteoarthritis Cartilage2008; 16:1110-7.
- Frank S, Schulthess T, Landwehr R, et al. Characterization of the matrilin coiled-coil domains reveals seven novel isoforms. J. Biol. Chem.2002; 277:19071-9.
- Chen Q, Johnson DM, Haudenschild DR, et al. Progression and recapitulation of the chondrocyte differentiation program: cartilage matrix protein is a marker for cartilage maturation. Dev. Biol.1995; 172:293-306.
- Stokes DG, Liu G, Coimbra IB, et al. Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum2002; 46:404-19.
Buffer:
MATN3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Chicken: (85%)
Immunogen:
MATN3 antibody was raised against a 13 amino acid synthetic peptide from near the center of human MATN3.
The immunogen is located within amino acids 180 - 230 of MATN3.
The immunogen is located within amino acids 180 - 230 of MATN3.
NCBI Gene ID #:
4148
NCBI Official Name:
matrilin 3
NCBI Official Symbol:
MATN3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAI39908
Protein GI Number:
146218451
Purification:
MATN3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
Swissprot #:
O15232
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | MATN3 Peptide | PSI-5141P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|